Bergeron, Jean

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 2,296

Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk

Després, J.-P., Lemieux, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E., Rodés-Cabau, J., Bertrand, O. F., & Poirier, P. (2008) · Arteriosclerosis Thrombosis and Vascular Biology

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 1,589

Hypertriglyceridemic Waist: A Marker of the Atherogenic Metabolic Triad (Hyperinsulinemia; Hyperapolipoprotein B; Small, Dense LDL) in Men?

Lemieux, I., Pascot, A., Couillard, C., Lamarche, B., Tchernof, A., Alméras, N., Bergeron, J., Gaudet, D., Tremblay, G., Prud’homme, D., et al. (2000) · Circulation

Diabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

Cited by 937

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 669

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Moriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 470

Effects of Endurance Exercise Training on Plasma HDL Cholesterol Levels Depend on Levels of Triglycerides: Evidence From Men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study

Couillard, C., Després, J.-P., Lamarche, B., Bergeron, J., Gagnon, J., Leon, A. S., Rao, D. C., Skinner, J. S., Wilmore, J. H., & Bouchard, C. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthCardiovascular and exercise physiology

Cited by 331

Postprandial triglyceride response in visceral obesity in men

Couillard, C., Bergeron, N., Prud'homme, D., Bergeron, J., Tremblay, A., Bouchard, C., Mauriège, P., & Després, J. P. (1998) · Diabetes

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 271

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., et al. (2021) · The Lancet Diabetes & Endocrinology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 232

Adiponectinemia in Visceral Obesity: Impact on Glucose Tolerance and Plasma Lipoprotein and Lipid Levels in Men

Côté, M., Mauriège, P., Bergeron, J., Alméras, N., Tremblay, A., Lemieux, I., & Després, J.-P. (2005) · The Journal of Clinical Endocrinology & Metabolism

Adipokines, Inflammation, and Metabolic DiseasesCardiovascular Disease and Adiposity

Cited by 230

Blood lipid response to 20 weeks of supervised exercise in a large biracial population: The HERITAGE family study

Leon, A. S., Rice, T., Mandel, S., Despres, J.-P., Bergeron, J., Gagnon, J., Rao, D. C., Skinner, J. S., Wilmore, J. H., & Bouchard, C. (2000) · Metabolism

Cardiovascular and exercise physiologyLipoproteins and Cardiovascular Health

Cited by 176

Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update

Mancini, G. B. J., Tashakkor, A. Y., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D. S., et al. (2013) · Canadian Journal of Cardiology

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 173

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia

Hegele, R. A., Berberich, A. J., Ban, M. R., Wang, J., Digenio, A., Alexander, V. J., D'Erasmo, L., Arca, M., Jones, A., Bruckert, E., et al. (2018) · Journal of Clinical Lipidology

Lipid metabolism and disordersLymphatic Disorders and Treatments

Cited by 165

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

Rosenson, R. S., Gaudet, D., Ballantyne, C. M., Baum, S. J., Bergeron, J., Kershaw, E. E., Moriarty, P. M., Rubba, P., Whitcomb, D. C., Banerjee, P., et al. (2023) · Nature Medicine

Lipid metabolism and disordersPancreatitis Pathology and Treatment

Cited by 140

Variability in the Response of HDL Cholesterol to Exercise Training in the HERITAGE Family Study

Leon, A. S., Gaskill, S. E., Rice, T., Bergeron, J., Gagnon, J., Rao, D. C., Skinner, J. S., Wilmore, J. H., & Bouchard, C. (2002) · International Journal of Sports Medicine

Cardiovascular and exercise physiologyLipoproteins and Cardiovascular Health

Cited by 116

Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial

Lemieux, P., Weisnagel, S. J., Caron, A. Z., Julien, A.-S., Morisset, A.-S., Carreau, A.-M., Poirier, J., Tchernof, A., Robitaille, J., Bergeron, J., et al. (2019) · European Journal of Endocrinology

Vitamin D Research StudiesDiabetes Treatment and Management

Cited by 102

Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula

Sniderman, A. D., Blank, D., Zakarian, R., Bergeron, J., & Frohlich, J. (2003) · Clinical Biochemistry

MicroRNA in disease regulationRetinal Diseases and Treatments

Cited by 100

Increased body fat mass explains the positive association between circulating estradiol and insulin resistance in postmenopausal women

Marchand, G. B., Carreau, A.-M., Weisnagel, S. J., Bergeron, J., Labrie, F., Lemieux, S., & Tchernof, A. (2018) · American Journal of Physiology-Endocrinology and Metabolism

Menopause: Health Impacts and TreatmentsEstrogen and related hormone effects

Cited by 73

The hypertriglyceridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify high-risk men with an altered cardiometabolic risk profile.

Blackburn, P., Lemieux, I., Alméras, N., Bergeron, J., Côté, M., Tremblay, A., Lamarche, B., & Després, J.-P. (2009) · Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

Cited by 67

Inflammatory markers and long-term risk of ischemic heart disease in men

St-Pierre, A. C., Cantin, B., Bergeron, J., Pirro, M., Dagenais, G. R., Després, J.-P., & Lamarche, B. (2005) · Atherosclerosis

Lipoproteins and Cardiovascular HealthInflammatory Biomarkers in Disease Prognosis

Cited by 67

Familial aggregation of blood lipid response to exercise training in the health, risk factors, exercise training, and genetics (HERITAGE) Family Study.

Rice, T., Després, J.-P., Pérusse, L., Hong, Y., Province, M. A., Bergeron, J., Gagnon, J., Leon, A. S., Skinner, J. S., Wilmore, J. H., et al. (2002) · Circulation

Genetics and Physical PerformanceLipoproteins and Cardiovascular Health

Cited by 65

Measuring insulin sensitivity in postmenopausal women covering a range of glucose tolerance: comparison of indices derived from the oral glucose tolerance test with the euglycemic-hyperinsulinemic clamp

Piché, M.-È., Lemieux, S., Corneau, L., Nadeau, A., Bergeron, J., & Weisnagel, S. J. (2007) · Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 31

Natural History (up to 15 years) of Platelet Count in 84 Patients with Familial Hyperchylomicronemia Due to Lipoprotein Lipase Deficiency

Gaudet, D., Baass, A., Tremblay, K., Brisson, D., Laflamme, N., Paquette, M., Dufour, R., & Bergeron, J. (2017) · Journal of Clinical Lipidology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 19

Effect of obesity on HDL and LDL particle sizes in carriers of the null P207L or defective D9N mutation in the lipoprotein lipase gene: the Québec LipD Study

Ruel, I. L., Gaudet, D., Perron, P., Bergeron, J., Julien, P., & Lamarche, B. (2003) · International Journal of Obesity

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 18